Companies · USAspending parent record
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Stock ticker: TEVA. 1 recipient record grouped under this USAspending parent (UEI DYLJM9RQJ167).
obligated to date on 2 non-competed awards of $1M+ signed FY2024–26
Not recently updated
Obligated to date, not spending in a year. Selected awards only (rule r5-v1): not this company's not-competed share.
2 non-competed ($1M+) · 0 other ($10M+)
Not recently updated
obligated to date: SPE2DP24F1238, Department of Defense, signed FY2024
Not recently updated
reported in TEVA by 1 member of Congress
Filings: House 2021–2026 · Senate 2024–2026
Federal contract awards in our records
Each row is one prime contract award on USAspending.gov; “USAspending” opens its official page.
What this table covers: every award signed in FY2024–26 that the agency coded “not competed” and that is $1 million or more, plus any award of $10 million or more (rule r5-v1). Smaller competed awards are not in it, so it is not this company’s total federal business and it cannot show a not-competed share. “Obligated to date” is the total committed on the award so far, including later modifications (USAspending, as of Oct 3, 2026), not the amount at any earlier date.
| Signed in | Non-competed awards | Obligated to date | Other awards $10M+ | Obligated to date |
|---|---|---|---|---|
| FY2024 | 2 | $4.0M | None in this set | — |
| FY2025 | None in this set | — | None in this set | — |
| FY2026incomplete | None in this set | — | None in this set | — |
FY2026 is incomplete: the Department of Defense reports contract actions 90 days late, and older awards keep growing through modifications, so these amounts will rise. Source: USAspending.gov, as of Oct 3, 2026.
| Source | ||||||
|---|---|---|---|---|---|---|
| SPE2DP24F1238Order under IDV SPE2DP20D00028510325537!ADENOVIRUS TYPE 4 A | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | Dec 14, 2023FY2024 | Not competedOnly one source-other (FAR 6.302-1 other) | $2,443,150 | USAspending |
| SPE2DP24F1236Order under IDV SPE2DP20D00028510325475!ADENOVIRUS TYPE 4 A | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | Dec 14, 2023FY2024 | Not competedOnly one source-other (FAR 6.302-1 other) | $1,526,969 | USAspending |
FY2024 awards to TEVA PHARMACEUTICAL INDUSTRIES LTD., largest first (obligated to date)
- SPE2DP24F1238Order under IDV SPE2DP20D00028510325537!ADENOVIRUS TYPE 4 ATEVA PHARMACEUTICALS USA, INC.
- Agency
- Department of Defense
- Signed
- Dec 14, 2023FY2024
- Competition
- Not competedOnly one source-other (FAR 6.302-1 other)
- Obligated to date
- $2,443,150
- SPE2DP24F1236Order under IDV SPE2DP20D00028510325475!ADENOVIRUS TYPE 4 ATEVA PHARMACEUTICALS USA, INC.
- Agency
- Department of Defense
- Signed
- Dec 14, 2023FY2024
- Competition
- Not competedOnly one source-other (FAR 6.302-1 other)
- Obligated to date
- $1,526,969
Recipient records grouped under this company (1)
USAspending groups recipients by its parent-company field, which has known errors. Check that the recipients below belong to TEVA PHARMACEUTICAL INDUSTRIES LTD.; the stock link below is made per recipient.
- TEVA PHARMACEUTICALS USA, INC.2 awards · 2 non-competed, $4.0M obligated to date
Stock ticker
Links between a federal contract recipient and an SEC-registered company, made by a written rule from SEC filings and USAspending records. Only confirmed links are shown.
How these recipients were linked (1)
- TEVA PHARMACEUTICALS USA, INC.subsidiary of the registrant (name match or SEC subsidiary list) · USAspending parent 'TEVA PHARMACEUTICAL INDUSTRIES LTD.' = registrant; recipient name starts with 'TEVA', a distinctive word of the parent name · rule r7-v1
A link says USAspending and SEC records tie this recipient to this registrant. It does not say a member’s trade or a company’s award means anything.
Members of Congress who reported trading this stock
Trades in TEVA from STOCK Act disclosures, newest filing first.
Two public records, side by side. The company holds federal contracts, and members reported trades in its stock. That is a pattern in the records, not an accusation: trades can be routine, made by a spouse or a managed account, and a sequence of events is not proof of wrongdoing. Amounts are the ranges members disclosed; they are never added up into a single figure, and “2 ×” means two same-day lots, each in that range.
1 member · 1 reported trade
| Alan Armstrong | R · OK · Senate | 1 | 1 | 0 | 0 | 0 | Jul 21, 2026 |
|---|
Members who reported trades in this stock, by number of reported trades
- R · OK · Senate
- Reported trades
- 1
- Purchases
- 1
- Sales
- 0
- Exchanges
- 0
- Options and other
- 0
- Latest filing
- Jul 21, 2026
Every reported trade, with its filing
| Filing | |||||
|---|---|---|---|---|---|
| Alan ArmstrongR · OK · Senate · owner: Self | TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | Purchase | $1,001–$15,000 | Mar 30 → Jul 21 | View filing |
Reported trades in TEVA, newest filing first
- Alan ArmstrongR · OK · Senate · owner: SelfTEVA Teva Pharmaceutical Industries Limited American Depositary Shares
- Type
- Purchase
- Amount (range)
- $1,001–$15,000
- Traded → filed
- Mar 30 → Jul 21
Looking for agency-level shares? See non-competed share by agency.